A group of investors led by LSP Life Sciences Partners of Amsterdam has put together €5 million that device company Activaero will use for continued development of its inhalation systems. Activaero recently initiated clinical studies involving the delivery of inhaled corticosteroids (ICS) using its Akita Jet nebulizer system. Read the company’s press release.
Activaero gets €5 million in new funding
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan